Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA submission; if currently outstanding warrants issued in previous financings are exercised in full for cash, it is anticipated that the cash runway would extend well beyond PMDA approval and into first commercial sales.

SUNNYVALE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- BioCardia(R), Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, sold 3,509,604 shares at an average price of $1.279 on Friday, June 5, 2026. No warrants were issued in this capital raise.

About BioCardia$(R)$

BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP(R) autologous and CardiALLO$(TM)$ allogeneic cell therapies are the Company's biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix(TM) biotherapeutic delivery and Morph(R) vascular navigation product platforms, and soon the Heart3D(TM) fusion imaging platform. BioCardia selectively partners on biotherapeutic delivery with peers developing important biologic therapies. For more information visit www.biocardia.com.

Upcoming Catalysts in 2026:

   -- CardiAMP HF Manuscript Published 
 
   -- CardiAMP HF Japan PMDA Submission Q4 2026 

Forward Looking Statements:

This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, statements relating to submission for and subsequent market clearance of the CardiAMP Cell Therapy. These forward-looking statements are made as of the date of this press release.

We may use terms such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should, " "approximately" or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. Factors that could cause or contribute to such differences include, but are not limited to, the Company's liquidity position and its ability to raise additional funds, as well as the Company's ability to successfully progress its clinical trials. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia's Form 10-K filed with the Securities and Exchange Commission on March 24, 2026, under the caption titled "Risk Factors" and in its subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Media Contact:

Miranda Peto, Investor Relations

Email: mpeto@BioCardia.com

Phone: 650-226-0120

Investor Contact:

David McClung, Chief Financial Officer

Email: investors@BioCardia.com

Phone: 650-226-0120

(END) Dow Jones Newswires

June 08, 2026 08:00 ET (12:00 GMT)